Table 3 IL-28B gene polymorphism in patients with chronic HCV infection and clinical characteristics of patients with different IL-28B SNPs
From: SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
Genotype | SNP | Percent | Age (y) | Sex (No. of Patients, %) | Viral Load (106 IU/mL), range | ALT (U/L), range | AST (U/L), range | |
|---|---|---|---|---|---|---|---|---|
(%) | Male | Female | ||||||
IL-28B rs8099917 | TT (n = 39) | 76.47 | 48 (25–64) | 54 (52.9) | 52 (47.1) | 7.98 (0.24–72.46) | 34 (18–179) | 38 (17–203) |
TG + GG (n = 12) | 23.43 | 47 (22–58) | 21 (55.3) | 16 (44.7) | 9.25 (0.89–59.71) | 36 (28–150) | 40 (24–138) | |
IL-28B rs12979860 | CC (n = 39) | 76.47 | 49 (22–64) | 57 (52.3) | 52 (47.7) | 10.23 (1.02–68.52) | 35 (21–112) | 32 (19–143) |
CT + TT (n = 12) | 23.43 | 49 (20–58) | 18 (52.9) | 16 (47.1) | 8.72 (0.48–65.32) | 37 (19–135) | 34 (17–178) | |
IL-28B rs12980275 | AA (n = 37) | 72.55 | 47 (28–64) | 51 (51.5) | 48 (48.5) | 11.25 (1.37–66.68) | 38 (22–144) | 31 (20–123) |
AG + GG (n = 14) | 27.45 | 46 (25–59) | 24 (54.5) | 20 (45.5) | 9.67 (0.69–71.26) | 32 (19–179) | 29 (17–112) | |
Z = 0.125 | chi-squared = 0.413 | Z = 0.579 | Z = 0.378 | Z = 2.143 | ||||
P value | .912 | .648 | .825 | .617 | .346 | |||